Pfizer Inc. (PFE)
Should You Pick PFE Stock At $25?
Pfizer stock (NYSE: PFE) recently reported its Q4 results, with revenues and earnings exceeding the street estimates. The company reported revenue of $17.8 billion and adjusted earnings of $0.63 per share, compared to the consensus estimates of $17.4 billion and $0.46, respectively.
Why Investors Need to Take Advantage of These 2 Medical Stocks Now
Finding stocks expected to beat quarterly earnings estimates becomes an easier task with our Zacks Earnings ESP.
Pfizer, Inc. (PFE) Q4 2024 Earnings Call Transcript
Pfizer, Inc. (NYSE:PFE ) Q4 2024 Earnings Conference Call February 4, 2025 10:30 AM ET Company Participants Francesca DeMartino - Senior Vice President, Chief Investor Relations Officer Albert Bourla - Chairman and Chief Executive Officer Dave Denton - Chief Financial Officer and Executive Vice President Chris Boshoff - Chief Scientific Officer and President of Research & Development Aamir Malik - Chief U.S. Commercial Officer and Executive Vice President Alexandre de Germay - Executive Vice President & Chief International Commercial Officer Andrew Baum - Chief Strategy & Innovation Officer and Executive Vice President Conference Call Participants Steve Scala - TD Cowen Geoff Meacham - Citibank Chris Schott - JPMorgan Vamil Divan - Guggenheim Securities Courtney Breen - Bernstein Evan Seigerman - BMO Capital Markets Kripa Devarakonda - Truist Securities Terence Flynn - Morgan Stanley Mohit Bansal - Wells Fargo David Risinger - Leerink Partners Trung Huynh - UBS Akash Tewari - Jefferies Chris Shibutani - Goldman Sachs Alexandria Hammond - Wolfe Research Tim Anderson - Bank of America Operator Good day, everyone, and welcome to Pfizer's Fourth Quarter 2024 Earnings Conference Call. Today's call is being recorded.
Pfizer's Q4 Earnings Beat Estimates, Non-Covid Drugs Drive Sales
PFE beats fourth-quarter estimates for earnings and sales. It maintains 2025 guidance.
Pfizer's fourth quarter sales and earnings top expectations
Pfizer Inc (NYSE:PFE, ETR:PFE) posted stronger-than-expected financial results for the fourth quarter and reaffirmed its 2025 revenue guidance. The company continues to expect between $61 billion and $64 billion in revenue this year, with sales from Covid products expected to be stable year-over-year.
Compared to Estimates, Pfizer (PFE) Q4 Earnings: A Look at Key Metrics
The headline numbers for Pfizer (PFE) give insight into how the company performed in the quarter ended December 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
PFE's Colorectal Cancer Drug Meets Other Dual Primary Goal of PFS
Pfizer's late-stage BRAF V600E-mutant mCRC study of the Braftovi combo regimen meets its other dual primary endpoint of PFS with statistical significance.
Pfizer Beats Q4 Revenue, EPS Estimates
Pharmaceuticals giant Pfizer (PFE -0.21%) reported fourth-quarter and full-year 2024 earnings on Tuesday, Feb. 4, that topped analysts' consensus estimates. The company reported an adjusted earnings per share of $0.63, significantly above the analyst consensus of $0.47, while generating revenue of $17.76 billion, surpassing expectations of $17.35 billion.
Pfizer (PFE) Beats Q4 Earnings and Revenue Estimates
Pfizer (PFE) came out with quarterly earnings of $0.63 per share, beating the Zacks Consensus Estimate of $0.48 per share. This compares to earnings of $0.10 per share a year ago.
Mizuho's Jared Holz on Merck and Pfizer Q4 results, 2025 outlook for Big Pharma stocks
Jared Holz, Mizuho Securities America healthcare sector strategist, joins 'Squawk Box' to break down the quarterly earnings results of Merck and Pfizer, 2025 outlook for pharmaceutical stocks, and more.
Pfizer stock climbs on Q4 revenue and earnings beat, reaffirmed guidance
“We remain confident in our ability to return to pre-pandemic operating margins in the coming years,” said Pfizer CFO David Denton.
Pfizer tops earnings estimates as Covid product sales beat expectations and cost cuts pay off
Pfizer reported fourth-quarter earnings and revenue that beat estimates as sales of the company's Covid products came in higher than expected and cancer drugs from Seagen boosted revenue. The results cap off a critical year for Pfizer, which has been slashing costs as it recovers from the rapid decline of its Covid business and stock price over the last two years.
